Markus Warmuth, Monte Rosa Therapeutics CEO

With a fresh $100M, Monte Rosa CEO de­tails plans to move sev­er­al mol­e­c­u­lar glues in­to the clin­ic

Monte Rosa Ther­a­peu­tics CEO Markus War­muth ex­pects mol­e­c­u­lar glues to make up a new class of drugs with “al­most un­lim­it­ed po­ten­tial” in the long run …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.